Teva & Medincell Advance BEPO® Long‑Acting Injectables: Regulatory Wins & Market Expansion
Teva’s partnership with Medincell advances BEPO® long‑acting injectables, securing FDA/EMA approvals, expanding U.S., Canada and South Korean markets, and boosting psychiatric therapeutic reach.
3 minutes to read